National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

About NIAID
 Overview
 Organization
  Organizational Charts
  Office of the Director
  DAIDS
   CIPRA
  DAIT
  DCR
  DEA
  DIR
  DMID
  VRC
 Director's Page
 Working at NIAID
 Finding People
 Visitor Information


Division of Acquired Immunodeficiency Syndrome (DAIDS)

Basic Sciences Program (BSP)

Basic science research efforts by NIAID funded investigators have yielded important scientific contributions, including new targets for vaccines, drugs, and microbicides. The DAIDS Basic Sciences Program (BSP), consisting of the Pathogenesis and Basic Research Branch, Targeted Interventions Branch and Epidemiology Branch, supports a major component of NIAID’s HIV/AIDS basic research efforts by carrying out the following activities:

  • Oversees grants and contracts that support basic and applied preclinical research
  • Encourages collaborative research with other scientific fields such as basic virology, immunology and pathobiology
  • Supports epidemiologic studies that help answer questions about HIV transmission and disease, including the Multicenter AIDS Cohort Study (MACS), Women's Interagency HIV Study (WIHS), and International Epidemiologic Databases to Evaluate AIDS (IeDEA)
  • Promotes research programs to discover novel therapeutic, vaccine, and microbicide strategies for the treatment and prevention of HIV
  • Coordinates research activities in consultation and/or collaboration with other government agencies, international organizations, and other Institutes at the National Institutes of Health.
  • Provides scientific guidance to grantees and contractors

For information on NIAID’s basic science research efforts, visit the HIV Basic Science Research Area.

back to top


Highlights

Dr. Carl Dieffenbach Appointed Director of the NIAID Division of AIDS
Feb. 1, 2008

News Releases

Statement: NIAID Will Not Move Forward with the PAVE 100 HIV Vaccine Trial
July 17, 2008

NIAID Media Availability: Exhausted B Cells Hamper Immune Response to HIV
July 14, 2008

Bulletin: Anti-TB Drug Fails to Benefit HIV-Exposed Infants who were Unexposed to TB at Study Enrollment
July 10, 2008

Special Announcements

Status of NIAID Adenovirus-based Vaccine Studies

Considerations for HIV Vaccine Clinical Trials in Adolescents

Guidance regarding HIV anti-retroviral treatment in developing countries

Search in About NIAID
 
E-mail Icon E-mail this page
Print Icon Print this page

Highlights

Dr. Carl Dieffenbach Appointed Director of the NIAID Division of AIDS
Feb. 1, 2008

News Releases

Statement: NIAID Will Not Move Forward with the PAVE 100 HIV Vaccine Trial
July 17, 2008

NIAID Media Availability: Exhausted B Cells Hamper Immune Response to HIV
July 14, 2008

Bulletin: Anti-TB Drug Fails to Benefit HIV-Exposed Infants who were Unexposed to TB at Study Enrollment
July 10, 2008

Special Announcements

Status of NIAID Adenovirus-based Vaccine Studies

Considerations for HIV Vaccine Clinical Trials in Adolescents

Guidance regarding HIV anti-retroviral treatment in developing countries